Beyer Stefanie, von Bueren André O, Klautke Gunther, Guckenberger Matthias, Kortmann Rolf-Dieter, Pietschmann Sophie, Müller Klaus
Center for Dentistry and Oral Medicine, University Medical Center Leipzig, Leipzig, Saxony, Germany.
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University Medical Center Goettingen, Goettingen, Lower Saxony, Germany.
PLoS One. 2016 Feb 9;11(2):e0148312. doi: 10.1371/journal.pone.0148312. eCollection 2016.
Our aim was to determine the characteristics, treatments and outcomes of patients with primary spinal glioblastomas (GB) or gliosarcomas (GS) reported in literature until March 2015. PubMed and Web of Science were searched for peer-reviewed articles pertaining to cases of glioblastomas / gliosarcomas with primary spinal origin, using predefined search terms. Furthermore we performed hand searches tracking the references from the selected papers. Eighty-two articles published between 1938 and March 2015 were eligible. They reported on 157 patients. Median age at diagnosis was 22 years. The proportion of patients who received adjuvant chemo- or radiotherapy clearly increased from the time before 1980 until present. Median overall survival from diagnosis was 8.0 ± 0.9 months. On univariate analysis age influenced overall survival, whereas tumor location, gender and the extent of initial resection did not. Outcomes did not differ between children (< 18 years) and adults. However, the patients who were treated after 1980 achieved longer survival times than the patients treated before. On multivariable analysis only age (< 60 years) and the time period of treatment (≥ 1980) were confirmed as positive independent prognostic factors. In conclusion, primary spinal GB / GS mainly affect younger patients and are associated with a dismal prognosis. However, most likely due to the increasing use of adjuvant treatment, modest therapeutic progress has been achieved over recent decades. The characteristics and treatments of primary spinal glioblastomas should be entered into a central registry in order to gain more information about the ideal treatment approach in the future.
我们的目的是确定截至2015年3月文献报道的原发性脊髓胶质母细胞瘤(GB)或胶质肉瘤(GS)患者的特征、治疗方法及预后情况。使用预定义检索词在PubMed和Web of Science数据库中检索与原发性脊髓起源的胶质母细胞瘤/胶质肉瘤病例相关的同行评议文章。此外,我们还通过手工检索追踪所选论文的参考文献。1938年至2015年3月期间发表的82篇文章符合要求,共报道了157例患者。诊断时的中位年龄为22岁。从1980年以前到现在,接受辅助化疗或放疗的患者比例明显增加。诊断后的中位总生存期为8.0±0.9个月。单因素分析显示年龄影响总生存期,而肿瘤位置、性别和初次切除范围则无影响。儿童(<18岁)和成人的预后无差异。然而,1980年后接受治疗的患者生存期比之前治疗的患者更长。多因素分析仅证实年龄(<60岁)和治疗时间段(≥1980年)为独立的阳性预后因素。总之,原发性脊髓GB/GS主要影响年轻患者,预后较差。然而,近几十年来可能由于辅助治疗的使用增加,已取得了一定的治疗进展。原发性脊髓胶质母细胞瘤的特征和治疗方法应纳入中央登记系统,以便未来获得更多关于理想治疗方法的信息。